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Abstract  
Background: Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for 
myelofibrosis (MI),  though  limited by a high rate  of transplant-related mortality (TRM).  In 
the present study we evaluate the outcome of MI patients undergoing an allogenic SCT after 
reduced intensity conditioning (RIC) regimens, and the impact of prognostic factors.  
Design and methods: Fifty two patients were transplanted in 26 Italian centres between 1998 
and 2006. We analyzed the influence of patient and disease clinical features before SCT and of 
transplant procedures on TRM and overall survival (OS) by means of univariate and 
multivariate analyses. 
Results: At SCT,  median age was 52,5 years (32-68) and  89% of the patients had  an 
intermediate or high Dupriez score. Conditioning regimens were based on fludarabine plus 
busulphan in 27% of patients, thiotepa plus cyclophosphamide in 46% and miscellaneous 
drug combinations in the other 27% of cases. Stem cells came from matched sibling donors 
for 75% of the patients and mismatched sibling or unrelated donors for the remaining 25%. 
The cumulative incidence of engraftment at day 90 after transplant was 83% (95% CI, 0.87-
0.97). The estimated 1-year TRM was 30%.  The estimated 3-year event-free-survival (EFS) 
and OS after hematopoietic SCT was 44%  and 38% respectively. In multivariate analysis, an 
higher leukocyte count and circulating blasts in the peripheral blood before SCT significantly 
reduced EFS and OS respectively.  
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Interpretation and conclusions: We conclude that the extension of the disease before 
transplantation based on the presence of circulating blasts and high leukocyte counts 
significantly affected the outcome after HSCT 
  
Introduction: Myelofibrosis (MI) is a clonal 
hematopoietic stem cell disorder that is clinically 
characterized by progressive anemia, marked 
splenomegaly, extramedullary hematopoiesis, 
constitutional symptoms and a significant risk of 
evolution into acute leukaemia. MI can appear as a 
primitive or idiopathic disorder or, less frequently, 
as a secondary complication of essential 
thrombocythemia or polycythemia vera, with a 
clinical presentation and course similar to the 
idiopathic form. The disease affects mainly elderly 
people, with a median age at diagnosis of about 65 
years. It is a heterogeneous disorder in term of 
presentation and evolution, with a median overall 
survival (OS) varying between 2 and 15 years, 
depending on the presence or absence of clinically 
defined prognostic factors.  Adverse prognostic 
factors for survival have included advanced age, 
marked anemia, leukocytosis or leukopenia, 
abnormal karyotype, constitutional symptoms and 
presence of circulating blasts  Moreover, the 
prognostic value of cytogenetic abnormalities, 
increased number of circulating CD34+ cells in 
peripheral blood and JAK2 mutational status has 
been also evaluated.   The available prognostic 
score systems are mainly based on clinical 
variables. The most widely used is the Dupriez 
score1, which is based on hemoglobin level and 
leukocyte count. The Mayo Clinic Group tried to 
improve the Lille score by adding 
thrombocytopenia and monocytosis.2 The 
International Working Group for Myelofibrosis 
Research and Treatment (IWGMRT) recently 
proposed a new scoring system analyzing the 
largest patient population and recognized 5   main 
unfavourable variables which were: age > 65 years, 
presence of constitutional symptoms, and 
circulating blasts cells ≥ 1% , anemia and  
leucocytosis.3 All these prognostic systems could 
clearly separate  intermediate or high risk patients 
(with a median survival ranging between 1 and 4 
years)  from patients with a favourable prognosis 
(median survival of 8-10 years).  
Drug therapy is aimed at alleviating the 
symptoms, and has not been shown to improve 
survival. Allogeneic hematopoietic stem cell 
transplantation (HSCT) is the only treatment with 
the potential for curing MI and has been performed 
in patients with unfavourable clinical variables for 
several years. The application of HSCT in MI is 
strongly limited by an unacceptable rate of 
transplantation-related toxicity occurring in patients 
receiving standard myeloablative conditioninig. In 
fact, transplant-related mortality (TRM)  ranged 
from 25 to 48% in different studies.4-9 The 
discovery that allogeneic stem cell can engraft 
patients prepared with nonmyeloablative doses of 
radiochemotherapy has led to the rapid 
development of a variety of reduced-intensity 
conditioning (RIC) regimens that have been 
successfully applied to patients with MI who would 
not be candidate for standard myeloablative HSCT 
due to advanced age or co-morbidities. RIC 
regimens might theoretically be applied to a large 
number of patients with an older age and 
comorbidities, while maintaining the potential for 
eradicating the disease based on the graft-versus MI 
effect.10-14 Studies in small series of patients who 
underwent RIC  HSCT demonstrated the feasibility 
of the procedure, and reported encouraging TRM 
rates below 15% and OS rates around 80%. 
However, the patients included were a few and the 
follow-up was still short. RIC regimens were 
heterogeneous and included fludarabine plus low 
dose TBI or alkylating agent (busulfan or 
melphalan).  
We have already published the analysis of the 
data of the Gruppo Italiano Trapianto Midollo 
Osseo (G.I.T.M.O.) Registry regarding a total of 
100 patients with MI, who underwent allogeneic  
HSCT in 26 different Italian Transplant Centres 
between 1986 and 2005.15 Herein we present a sub-
analysis limited to the patients who had received 
RIC regimens in more recent years, with the aim of 
analysing clinical features of patients and 
transplants and identifying  prognostic factors 
affecting the outcome after HSCT. 
 
Methods: Data were collected in an XLS database 
and imported into Stata/SE 9.0 for Windows for the 
statistical analysis.  The end-points were 
engraftment, acute and chronic graft-versus-host 
disease (GVHD), relapse, TRM, overall survival 
(OS) and event-free survival (EFS).   
TRM was defined as  death due to all causes not 
related to MI.  OS  was defined as the time 
(months) from date of transplant to either death or 
last observation. EFS was defined as the time from 
date of transplant to  relapse, death or last 
observation.  OS and EFS were described using the 
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Kaplan-Meier approach. Analysis of survival was 
done using Cox proportional hazard models, after 
the proportional hazards assumption had been 
verified. All variables considered in univariate 
analysis as possible prognostic factors were: 
primary diagnosis (primary or secondary MI), 
Dupriez score at transplant (low, intermediate, or 
high), transplant time (before and after 2001), 
interval between diagnosis and transplantation 
(months), transfusions before transplant, 
hemoglobin levels, leukocyte cell counts, 
circulating blasts, karyotype, previous splenectomy, 
splenomegaly at transplantation, age at 
transplantation, drugs of the conditioning regimen 
(fludarabine plus busulphan or thiotepa plus 
cyclophosphamide or other miscellaneous 
regimens), source of stem cells (marrow or 
peripheral blood), acute GVHD (grade 0-I or grade 
II-IV), and chronic GVHD (absent or limited or 
extensive). Multivariate stepwise analyses included 
all variables significant at p≤0.10 in an univariate 
analysis. Retention in the stepwise model required  
the variable to be significant at p≤0.05 in a 
multivariate analysis. 
Results: A total of 52 patients were 
transplanted between January 1998 and December 
2006. (table 1 and 2). Median time between 
diagnosis and HSCT was 13 months (1-161). At the 
time of HSCT, median age was 52,5 years (32-68), 
89% of the patients had a Dupriez score ≥ 1, 45% 
had previously received  red cells transfusions, 27% 
had blasts in the peripheral blood, 22 % had an 
abnormal karyotype,  51% had splenomegaly, 43% 
underwent splenectomy before HSCT. Conditioning 
regimens were based on fludarabine plus busulphan 
in 27% of patients, thiotepa plus cyclophosphamide 
in 46% and miscellaneous drug combinations in the 
other 27% of cases.   Stem cells came from matched 
sibling donors for 75% of the patients and 
mismatched sibling or unrelated donors for the 
remaining 25%.  Thirty-five per cent received bone 
marrow and 65% peripheral blood stem cells.  
Median time of follow-up after HSCT was 13 
months for the whole population and 34 months for 
surviving patients. Eighty-three per cent achieved 
full engrafment. Eighteen patients developed acute 
GVHD grades II to IV for a cumulative incidence 
of38% by day 100 after transplantation (95% CI 
0.9-1.3). Chronic GVHD occurred in 20 patients for 
a cumulative incidence of 50% at 2 years (95% 
CI0.4-0.8): it was limited in 14 patients and 
extensive in 6 patients. One-year TRM was 30%.  
The cumulative incidence of relapse was 19% at 1 
year. 
Table 1: Clinical and haematological characteristics of the 
patients at allergeneic stem cell transplantation. 
Total no. Patients 52 
  
  
Age    
Median (range) 52,5 (32-68) 
    
Diagnosis   
Idiopathic   myelofibrosis 36/44 (82%) 
Secondary  myelofibrosis 8/44(18%) 
     
Time diagnosis-SCT ( months)   
Median (range) 13 (1-162) 
≤ 12 21/52 (40%) 
13-35 14/52 (27%) 
≥ 36 17/52 (33%) 
    
Dupriez score at transplant   
Low 5/44 (11%) 
Intermediate 30/44 (68%) 
High 9/44 (21%) 
    
Previous transfusions 18/40 (45%) 
    
Karyotype   
Normal 28/36 (78%) 
Abnormal 8/36 (22%) 
    
Previous splenectomy 20/46 (43%) 
    
Splenomegaly at transplant 22/43 (51%) 
    
Circulating blasts at transplant 11/41 (27%) 
  
  
Hemoglobin level at transplant (g/dl)   
Median (range) 9.1 (5.6-14.4) 
    
White cell count at transplant (x 106/l)   
Median (range) 7.7 (0.6-118) 
 
The estimated 3-year EFS and OS were respectively 
44% and 38%.  In univariate analysis factors 
associated with an higher TRM rate were: an older  
transplant date (1998-2000 vs 2001-2006: 
HR=0.25; CI95%[0.09;0.68]; p=0.007) and  presence 
of  grade II-IV acute GVHD (HR 2.42; CI95%[0.92-
6.38]; p=0.073), The final survival model did not 
show any significant prognostic factor for TRM. 
Prognostic factors that were significantly 
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Table 2: Transplant-related characteristics 
Year of the transplant   
1998-2000 8/52 (15%) 
2001-2006 44/52  (85%) 
    
Donor   
HLA matched sibling 39/52 (75%) 
Unrelated or  HLA  “mismatched” sibling 13/52 (25%) 
    
Source    
Bone marrow 18/52 (35%) 
Peripheral blood 34/52 (65%) 
    
Conditioning regimen   
Fludarabine plus busulphan 14/52 (27%) 
Thiotepa plus cyclophosphamide 24/52 (46%) 
Fludarabine- 2 Gy TBI 4/52 ( 8%) 
Fludarabine-melphalan 6/52  (11%) 
Other 4/52  (8%) 
 
(p≤0.10) associated with EFS in the univariate 
proportional hazards model were: transplant time 
(1998-2000 vs 2001-2006: HR=0.46; 
CI95%[0.19;1.15]; p=0.098), leukocyte count before 
transplantation (HR=1.00002; CI95% 
[1.000002:1.000032]; p=0.028) and presence of 
chronic extensive GVHD (HR=0.27; CI95% 
[0.06;1.26]; p=0.095). In multivariate analysis only 
an higher leukocyte count before HSCT was 
significantly associated with an unfavourable EFS 
(HR=1.000028; CI95% [1.000011:1.000045]; 
p=0.001). In univariate analysis factors that affected 
OS were: presence of  blasts in the peripheral blood 
before transplantation (HR=3.37; CI95%[0.36;2.39]; 
p=0.020), an higher leukocyte count before 
transplantation (HR=1.00002; CI95% 
[1.000002:1.000035]; p=0.032), an older  transplant 
date (1998-2000 vs 2001-2006: HR=0.32; CI95% 
[0.21;0.82]; p=0.018). In multivariate analysis    
circulating blasts in the peripheral blood before 
transplantation significantly reduced OS 
(HR=3.356; CI95%[1.21;9.34]; p=0.020).  
 
Discussion: We recently reported data on a 
population of 100 patients with MI who underwent 
allogeneic HSCT in 26 transplant centers that are 
part of the GITMO in a 20-year period between 
1986 and 2006 and we retrospectively analyzed the 
influence of patient and disease clinical features 
before SCT and of transplant procedures on TRM 
and OS.15 We confirmed that MI remains a rare 
indication for SCT with the recruitment of about 
15-17 cases per year since 2002 and observed a 
great heterogeneity in terms of conditioning 
regimens, GHVD prophylaxis and supportive 
measures. Although  we observed a significative 
and progressive  improvement of TRM after 1996, 
we could not recognized any significative difference 
in outcome either between patients treated with 
myeloablative versus RIC regimens or among those 
treated with  different  regimens. The lack of any 
association between intensity of conditioning or 
type of drugs included in the preparative regimen 
could be in part due to the great heterogeneity of 
transplant procedures. The present analysis is 
limited to  the patients who had received RIC 
regimens , with the aim of  identifying  prognostic 
factors affecting the outcome after HSCT. This 
study confirms  that outcome after RIC transplants 
has been progressively improved in the last decade. 
However, transplant toxicity is still a matter of 
concern , since  we observed a 1- year TRM of 30% 
that is  higher than that reported in previously 
published series after RIC transplants (4-6) and 
similar to TRM observed after myeloablative 
transplants.10-14 The extension of the disease before 
transplantation based on the presence of circulating 
blasts and high leukocyte counts significantly 
affected both EFS and OS after HSCT.  These two 
parameters are both included in well-known 
prognostic scoring systems: the leukocyte count in 
the Dupriez score and the circulating blasts 
percentage in the IWGMRT one. These scoring 
systems, that were  validated in non-transplanted 
patients, have demonstrated to impact the outcome 
after the transplant, too. In our series of patients we 
could not identify any transplant procedure 
(conditioning regimen or stem cell source or donor) 
influencing outcome, probably because of the small 
number of patients examined and the heterogeneity 
of chemotherapy and immunosuppressive drugs 
delivered. However, the most commonly used RIC 
regimen was the association of thiotepa and 
cyclophosphamide, that was administered to nearly 
half of the patients. Thiotepa is known to be a 
radiomimetic drug with a potent myeloablative 
activity associated with an immunosuppressive 
effect and minimal toxicity. The combination of 
thiotepa and cyclophosphamide was originally 
described for autologous transplants,16 then it was 
incorporated in the conventional preparative 
regimens for T-cell depleted allogeneic SCT from 
HLA matched and haploidentical sibling donors.17-18 
The Genova group reported that thiotepa at the dose 
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Table 3. Summary of the previously reported clinical results of allogeneic stem cell transplantation following reduced-intensity-
conditioning  transplants in myelofibrosis. 
 
of 15 mg/kg and cyclophosphamide  at the dose of 
120-150 mg/kg produced complete engraftment and 
remission in 29 out of 31 patients, mostly with 
advanced disease.19 In a subsequent study, the same 
regimen with a 30% reduction of both drug doses 
was well tolerated by patients between 45 and 60 
years with advanced leukemias, although half of the 
patients had persisting or relapsing disease.20 The 
incorporation of thiotepa in RIC regimens have 
represented an innovation in several  Italian studies 
for different haematological diseases: thiotepa in 
association with cyclophosphamide and/or 
fludarabine  followed by haematopoietic stem cells 
have demonstrated high feasibility and effectiveness  
in elderly patients with  acute leukemias,20 in 
heavily pretreated relapsed or refractory 
lymphomas21 and in myelodisplastic syndromes.22 
How do our study results compare with those 
already reported? Table 3 summarized the clinical 
results of the studies published. Most of them were 
retrospective and include  small series of patients. 
The largest series was reported by Kroeger on 
behalf of the European Group for Blood and 
Marrow Transplantation.23 The study was 
prospective and included 104 patients mainly with 
intermediate or high risk score who received a 
conditioning regimen based on fludarabine 180 
mg/mq and busulfan 8 mg/kg i.v or 10 mg/Kg p.o 
and hematopoietic stem cells coming from sibling 
or unrelated donors. Engraftment was 99%; 1-year 
TRM was 16% and was significantly increased in 
patients older than 50 years, in cases with  
intermediate and high-risk MI and after transplants 
from mismatched donors .  Five-year OS was 67% 
and 5 –year EFS was 51%. Relapse rate was higher 
in splenectomized patients and if disease duration 
prior transplant was > 24 months. Moreover, 
Kroeger reported that this conditioning regimen 
induced a JAK-2 negativity in 78% of patients 
carrying the V617-JAK2 mutation before 
transplant24  and  produced  a rapid regression of 
bone marrow fibrosis in 59% of patients al day 
+100 and in 100% of patients at day +360.25 At 
present, the busulfan-fludarabine regimen could be 
considered as the RIC regimen that has been tested 
on the largest patient population and demonstrated 
the best results in terms of feasibility and clinical, 
molecular and histological responses. 
The largest single center experience was 
reported by Bacigalupo et al,26 concerning 46 
patients who had received a RIC regimen based on 
thiotepa and cyclophosphamide. TRM was 24% and 
5-year OS was 45% in the whole population, but it 
ranged from 8% to 77% according to the risk 
category.  One of the most important contributions 
of these recent studies is the identification of the 
 Rondelli10 Synder 12 Merup 14 Kroger 23 Bacigalupo 26 Present 
GITMO series 
N° pts 21 9 10 103 46 52 
Median age 54 (27-68) 54 (46-68) 40 (5-63) 51 (24-67) 55 (32-68) 52 (32-68) 
RIC 
Conditioning 
 
Fluda + busulfan 
Thiotepa+cy 
Fluda+ 
melphalan 
Fluda + TBI 
Fluda+ 
Melphalan 
 
Fluda + TBI 
Fluda+ busulfan 
 
Fluda+Cy+ 
melphalan 
Fluda + 
busulfan 
Thiotepa + cy 
±melphalan 
Fluda +  busulfan 
 
Thiotepa + cy 
Donor 
REL/UNREL 19/2 2/7 20/7 33/70 32/14 39/13 
Median 
follow-up 
survivors 
31 months 32 months 50 months 33 months 39 months 34 months 
1 y-TRM % 9% 44% 29% 16% 24% 30% ( at 1 y) 
3y- OS % 78% (at 2 y) 56% 70% 67% (at 5 y) 45% (at 5 y) 44% (at 3 y) 
3 y -relase 9% 0% Not evaluable 22 % 19% 19% 
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prognostic factors that influence the outcome after 
HSCT. Among the transplant-related variables,  
transplants from unrelated donors had a 
significative worse OS in comparison with sibling 
transplants in the Italian series15 and in the Genova 
study,26 while in the German study23 only 
mismatched unrelated donors had an unfavourable 
impact on OS. Among the disease-related variables, 
Dupriez score identified significative differences in 
the outcome after SCT in the German study,23 while 
Bacigalupo26 recognized  large splenomegaly and 
higher than 20 red cell transfusions  before 
transplant as powerful unfavourable predictors for 
OS. Role of splenectomy is still a controversial 
issue. Patients with large splenomegaly at transplant 
can have a slower granulocyte and platelet recovery, 
an higher risk of graft failure or persistence of 
splenomegaly for several months after transplant.27-
28 However, splenectomy  is associated of a 25% 
rate of bleeding and thrombotic complications and 
6% perioperative deaths in patients with 
myelofibrosis.29 The increased risk of relapse after 
transplant in splenectomized patients observed in 
the German study  was not confirmed in other series 
of patients. Since splenectomy is commonly 
performed in patients with larger splenomegaly, it 
can be hypothesized that splenectomy could be an 
indirect sign of a greater extension of the 
myeloproliferative disease before transplant, that  
could be associated to an higher risk of relapse after 
HSCT. 
 
Conclusions: In conclusion, these results indicate 
that allogeneic SCT may be an attractive treatment 
approach for patients with high-risk MI. Although 
the outcome has been significantly improved in the 
last decade due to the reduction of TRM, several 
issues such as the timing of HSCT, the  choice of 
the conditioning regimen, the source of stem cells, 
and  the donor type have not been fully understood.   
Prospective studies that will explore new transplant 
modalities with   the aims of reducing TRM and 
allow MI long-term control are warranted in this 
setting. The GITMO will promote a prospective 
study comparing two RIC regimes, fludarabine-
busulfan versus fludarabine-thiotepa in patients 
with high-risk MI. 
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